Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE Dual molecular targeted therapy for mTOR and PI3K may be a promising therapeutic strategy in the specific population of patients with lung cancer with LKB1 loss. 30825612 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE Mutations in EGFR, KRAS, BRAF, and PIK3CA genes are widely analyzed in solid tumors such as lung cancer, colorectal cancer, breast cancer, and melanoma. 29304903 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE Therefore, targeting the PI3K pathway may be a potential therapeutic strategy that prevents the structural skeletal damage associated with bone metastasis of lung cancer. 30896825 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE Long non-coding RNA OECC promotes cell proliferation and metastasis through the PI3K/Akt/mTOR signaling pathway in human lung cancer. 31452780 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 AlteredExpression disease BEFREE Consistently, DOK7V1 overexpression in lung cancer cells suppressed the phosphoinositide 3‑kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathways, but activated the focal adhesion kinase (FAK)/paxillin signaling pathway. 30431081 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE The phosphoinositide 3-kinase (PI3K)/AKT/mechanistic target of rapamycin (mTOR) signaling has been shown to contribute to tumorigenesis, tumor progression, and resistance to therapy in most human cancer types, including lung cancer. 31262325 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE Our studies suggest that miR-183-5p may function as a tumor suppressor in lung cancer via the miR-183-5p/PIK3CA regulatory axis and identify a potentially effective therapeutic strategy for lung cancer. 30528264 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE Co-mutations in <i>TP53</i> and the <i>PI3K/AKT/mTOR</i> pathway confer additional resistance to anti-HER2 treatments in lung cancer. 31748336 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 AlteredExpression disease BEFREE Finally, we identified that the PI3K-AKT and epilthelial-mesenchymal transition (EMT) signaling pathways were inhibited by miR-3666 overexpression in lung cancer cells. 30481052 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE Inotilone from Inonotus linteus suppresses lung cancer metastasis in vitro and in vivo through ROS-mediated PI3K/AKT/MAPK signaling pathways. 30787353 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE Additionally, Aclidinium Bromide suppressed the PI3K/AKT signaling pathway in lung cancer A549 cells. 31128006 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE Furthermore, cotreatment with sesamin and CAY10404 markedly reduced the levels of phosphorylated protein kinase B (pAkt) and phosoinositide 3 kinase (PI3K) in three lung cancer cell lines. 30365050 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 AlteredExpression disease BEFREE MicroRNA-374b accelerates the development of lung cancer through downregulating PTEN expression via activating PI3K/Akt pathway. 30779080 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE All of these results suggested that the lncRNA FER1L4 suppressed cell proliferation and metastasis by inhibiting the PI3K/Akt signaling pathway in lung cancer. 31115514 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE TP53, EGFR and PIK3CA gene variations observed as prominent biomarkers in breast and lung cancer by plasma cell-free DNA genomic testing. 31100334 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE To date, PI3K inhibitors have not been approved for lung cancer. 31337981 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE Methyl nonanoate, (R)-citronellol, cis-carveol (L-carveol), 3-methyl-Cyclohexanone, 4-carene and thujopsene were finally screened for PI3K targeted anti-cancer therapies which may find direct application as inhalers or sprays against lung cancer as these compounds are highly volatile. 28356026 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE The effect of paclitaxel combined with lobaplatin on the sensitivity of lung cancer cell line NCI-H446 through influencing the phosphatidylinositol 3-kinase (PI3K)/Akt pathway was investigated. 29616103 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE The mechanism may involve of PI3K/AKT signaling pathways in A549 cells, which may a potential therapeutic target for the treatment of lung cancer. 30344755 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE RAS signaling through PI3K is necessary for normal lymphatic vasculature development and for RAS-induced transformation in vitro and in vivo, especially in lung cancer, where it is essential for tumor initiation and necessary for tumor maintenance. 28847905 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE Fibroblast activation protein-α promotes the growth and migration of lung cancer cells via the PI3K and sonic hedgehog pathways. 29115573 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE These results suggest that 27HC promotes lung cancer cell proliferation via ERβ and PI3K-Akt signaling. 30190703 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 Biomarker disease BEFREE Taken together, these findings demonstrate that PI3K/AKT/YY1 is involved in the regulation of lung cancer cell behavior induced by IL‑13, and miR‑29a represents a promising therapeutic target. 29620222 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 AlteredExpression disease BEFREE IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling. 29516506 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.500 AlteredExpression disease BEFREE We demonstrated that regulation of JNK/ P38/PI3K by TGF-β1 led to down expression of NMII-A which promoted EMT and lung cancer metastasis. 28782471 2018